DBV Technologies S.A. DBVT
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026
DBV Technologies S.A. (DBVT) is a healthcare company listed in the US with a market value of about $693M. In fiscal year 2025 it had revenue of $6M and net income of -$147M, a net margin of -2607.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -13% a year, a 5-year average ROIC of -101%.
About DBV Technologies
DBV Technologies is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $7M in 2015 to $6M in 2025, a decline of about 1.7% a year. It was profitable in 2 of the last 10 years in our data. It spends 2070% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $4M | — | — | $6M | $11M | $15M | $17M | $14M | $10M |
| Net income | -$147M | -$114M | $73M | $96M | -$98M | -$160M | -$172M | -$190M | -$177M | -$121M |
| Free cash flow | -$122M | -$107M | -$80M | -$56M | -$109M | -$168M | -$154M | -$162M | -$146M | -$71M |
| EPS (diluted) | $-2.34 | $-1.81 | $1.16 | $1.53 | $-1.56 | $-2.54 | $-2.74 | $-3.02 | $-2.82 | $-1.92 |
| Net margin | -2607.3% | -2744.3% | — | — | -1713.5% | -1415.0% | -1169.5% | -1142.4% | -1240.2% | -1260.8% |
| ROIC | -66.3% | -268.2% | -41.4% | -38.7% | -89.3% | -71.9% | -61.3% | -106.1% | -85.4% | -46.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $41.93, 281% above the current price; targets range from $29.66 to $47.38; the consensus rating is “Buy”; expected EPS is $-0.41 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does DBV Technologies pay a dividend?
Not currently.
Is DBV Technologies a good stock to buy?
We do not give buy or sell advice. DBV Technologies scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.